Biodesix Q2 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $17.925M Beat $16.214M Estimate
Portfolio Pulse from Benzinga Newsdesk
Biodesix (NASDAQ:BDSX) reported Q2 2024 GAAP EPS of $(0.08), beating the $(0.09) estimate, and sales of $17.925M, surpassing the $16.214M estimate. This represents a significant improvement over the same period last year.
August 07, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biodesix reported better-than-expected Q2 2024 results with GAAP EPS of $(0.08) beating the $(0.09) estimate and sales of $17.925M surpassing the $16.214M estimate. This indicates strong performance and significant improvement over the same period last year.
The better-than-expected earnings and sales figures indicate strong operational performance and growth, which is likely to positively impact the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100